• What's involved: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
  • Take part: Open
  • Principal Investigator: Dr Maura Corsetti
Research Theme | Gastrointestinal & Liver | Open Trials

What's involved

A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis

Principal Investigator

Dr Maura Corsetti

Take part

Open
Back to all trials

Website by Volute